2019-02-12
NextCell listed on the Life Science Hotlist
NextCell Pharma AB ("NXTCL") announces that Invest Stockholm has now placed NXTCL on the Life Science Hotlist.
The Stockholm-Uppsala Life Science Investment Hotlist is curated by Invest Stockholm and lists the most promising and innovative companies active in the field of life science. NXTCL with both its stem cell banking and drug development business is an ideal candidate for this list.
The company develops novel treatments with stem cells from the umbilical cord. In umbilical cord and umbilical cord tissue there are young and viable stem cells that can be collected without any medical
NextCell Pharma AB ("NXTCL") announces that Invest Stockholm has now placed NXTCL on the Life Science Hotlist.
The Stockholm-Uppsala Life Science Investment Hotlist is curated by Invest Stockholm and lists the most promising and innovative companies active in the field of life science. NXTCL with...
Read moreRead more2019-02-07
NextCell´s CEO invited speaker at National conference on Clinical Studies
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 2019 National Conference on Clinical Studies.
The conference, which is held in Malmö and arranged by the national initiative Clinical Studies Sweden, a collaboration between Vetenskapsrådet (Swedish Research Council) and Sweden´s six healthcare regions, brings together researchers, politicians, and others who are active in the Life Science area. The scope of the event is knowledge exchange and networking, with the topic for the year being “The Value of Clinical studies”. Examples of issues
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 2019 National Conference on Clinical Studies.
The conference, which is held in Malmö and arranged by the national initiative Clinical Studies Sweden, a collaboration between Vetenskapsrådet (Sw...
Read moreRead more2019-02-05
Saving of stem cell from births increases significantly for NextCell´s biobank Cellaviva
Stem cell company NextCell Pharma AB (”NXTCL”) announces that Cellaviva’s sales has increased significantly from November 2018 to January 2019, as compared to the corresponding months previous year. It is partly a result of an increasing interest in stem cell saving in Sweden, and partly due to the expansion into Denmark.
Cellaviva offers new parents the opportunity to save their child´s stem cells for therapeutic treatment of diseases the family has suffered from, or risk being affected of in the future. Stem cells are collected from the umbilical cord after the umbilical cord has been cut
Stem cell company NextCell Pharma AB (”NXTCL”) announces that Cellaviva’s sales has increased significantly from November 2018 to January 2019, as compared to the corresponding months previous year. It is partly a result of an increasing interest in stem cell saving in Sweden, and partly due to t...
Read moreRead more2019-01-31
Iterim report quarter 1
First quarter (2018-09-01 till 2018-11-30)
· Net sales amounted to SEK 73,745 (158,354). Apart from the accrual effect, sales increased by 7 %.
· Operating result amounted to SEK -5,440,809 (-3,210,815).
· Earnings per share* amounted to SEK -0.51 (-0.38).
· Cash and bank amounted to SEK 10,437,405 (13,365,659).
· Solidity** amounted to 87 (59) %.
**Result per share: operating results divided by the average number of shares. Average number of shares for the first quarter of 2018/2019: 10,693,960 shares (8,505,425). Number of shares in NextCell as
First quarter (2018-09-01 till 2018-11-30)
· Net sales amounted to SEK 73,745 (158,354). Apart from the accrual effect, sales increased by 7 %.
· Operating result amounted to SEK -5,440,809 (-3,210,815).
· Earnings per share* amounted to SEK -0.51 (-0.38).
· Cash ...
Read moreRead more2019-01-30
Patients treated with ProTrans in phase II of the clinical trial
NextCell Pharma AB ("NextCell") hereby announces that they today have reached a significant milestone as they have now initiated the second part of the ProTrans-1 clinical trial. In addition to safety, clinical efficacy is evaluated, e.g. whether the patient's own insulin production improves 12 months after treatment with ProTrans compared to placebo. The phase-II part is randomized, double-blind, placebo-controlled which means that neither the patient nor the doctor knows what treatment the patient is receiving. So far, two patients have undergone treatment. In total, 15 patients will be
NextCell Pharma AB ("NextCell") hereby announces that they today have reached a significant milestone as they have now initiated the second part of the ProTrans-1 clinical trial. In addition to safety, clinical efficacy is evaluated, e.g. whether the patient's own insulin production improves 12 m...
Read moreRead more2018-12-05
NextCell strengthens the organization for continued growth
NextCell Pharma AB ("NextCell") hereby announces that the Board has decided to appoint Sofia Fredrikson to CFO in the company. Sofia Fredrikson will take office starting today. Former CFO, Leo Groenewegen, will continue to work for the company in the newly created role of Business Development Manager. Both Sofia Fredrikson and Leo Groenewegen will be part of NextCell's management team.
Sofia Fredrikson, born 1983, has been employed by NextCell since November 2018. The Board has now decided to appoint Fredrikson as CFO for the company. Sofia Fredrikson has worked as an authorized accountant
NextCell Pharma AB ("NextCell") hereby announces that the Board has decided to appoint Sofia Fredrikson to CFO in the company. Sofia Fredrikson will take office starting today. Former CFO, Leo Groenewegen, will continue to work for the company in the newly created role of Business Development Man...
Read moreRead more2018-11-28
NextCell CEO invited speaker at Karolinska Institutet Conference
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the Karolinska Institutet conference “From tissue to motion” - a 10-year anniversary.
The conference brings together different research groups within the field of regenerative medicine who will meet with entrepreneurs and life science companies for two days. The scope is to cover the very latest progress of the research in the multidisciplinary fields of regenerative medicine, motion and health.
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the Karolinska Institutet conference “From tissue to motion” - a 10-year anniversary.
The conference brings together different research groups within the field of regenerative medicine who will mee...
Read moreRead more2018-11-16
ProTrans trial is approved for high dose treatment in the phase II part
The stem cell company NextCell Pharma AB ("NXTCL") today announced that the Swedish Medical Product Agency has approved the amendment for treatment of patients in the ProTrans-1 trial with high dose of ProTrans in the randomized placebo-controlled part.
The ProTrans clinical trial is divided into a dose-scale part where 9 patients were treated with ProTrans during 2018. On October 25th, the Data Safety and Monitoring Board recommended the start of the second part of the trial with the dose that the study team found most appropriate.
The safety of ProTrans seem well tolerated, NXTCL
The stem cell company NextCell Pharma AB ("NXTCL") today announced that the Swedish Medical Product Agency has approved the amendment for treatment of patients in the ProTrans-1 trial with high dose of ProTrans in the randomized placebo-controlled part.
The ProTrans clinical trial is divided into...
Read moreRead more